Aandeel STAB STATERA BIOPHARMA, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Statera Biopharma, Inc. Nasdaq

Aandelen

STAB

US8575611046

Beurs gesloten - Nasdaq
Andere beurzen
 15:30:01 20-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,0007 USD 0,00% Intraday-grafiek van Statera Biopharma, Inc. 0,00% -99,98%
2022 Statera Biopharma, Inc. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022 CI
2022 Statera Biopharma, Inc. Rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2022 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Statera Biopharma : Material Agreement - Form 8-K
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
STATERA BIOPHARMA, INC. : Other Events (form 8-K)
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data
Top Premarket Gainers
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers STAB
  4. Koers STAB
  5. Nieuws Statera Biopharma, Inc.
  6. Andere talen
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU